海利生物: 海利生物简式权益变动报告书

Core Viewpoint - The report details a significant reduction in shareholding by the information disclosure obligor, Fang Zhangle, in Shanghai Haili Biotechnology Co., Ltd., resulting in a decrease of his shareholding percentage below 5% [1][7]. Group 1: Shareholding Changes - Fang Zhangle reduced his shareholding from 12,347,107 shares (1.88315%) to 5,790,607 shares (0.88317%) [6][7]. - Fang Wenyuan, the concerted actor, maintained her shareholding at 26,992,417 shares (4.11682%) [6][7]. - The total shareholding of both Fang Zhangle and Fang Wenyuan decreased from 39,339,524 shares (5.99997%) to 32,783,024 shares (4.99999%) [6][7]. Group 2: Purpose of Shareholding Change - The reduction in shareholding was driven by Fang Zhangle's personal funding needs, with no violations of shareholder reduction commitments or relevant regulations [5][6]. - There are plans for potential further reductions in shareholding within the next 12 months, depending on market conditions [5][6]. Group 3: Transaction Details - The share reduction occurred through centralized bidding transactions, with a total of 6,556,500 shares sold, representing a decrease of 0.99998% of the total share capital [6][10]. - Prior to this transaction, Fang Zhangle had also reduced his holdings by 8,291,600 shares (1.26461%) through block trading on April 8, 2025 [8][10]. Group 4: Compliance and Disclosure - The report confirms that all necessary authorizations and approvals for the shareholding changes have been obtained, and the disclosures comply with relevant laws and regulations [1][5]. - There are no restrictions on the shares held by the information disclosure obligors, such as pledges or freezes [8].